NSAID | IC50 (μM) | |
---|---|---|
TPα cross-linking1-a | Cell growth1-b | |
Acetaminophen* | >10000 | 21000 ± 14000 |
Aspirin* | 9300 ± 4700 | 1770 ± 640 |
Diclofenac* | 160 ± 90 | 120 ± 110 |
Diflunisal | 80 ± 30 | 160 ± 80 |
Ibuprofen* | 2300 ± 600 | 290 ± 160 |
Indomethacin* | 150 ± 40 | 200 ± 130 |
Meclofenamate | 90 ± 50 | 120 ± 70 |
Mefenamate | 220 ± 60 | 200 ± 60 |
Naproxen* | 1200 ± 400 | 660 ± 460 |
Niflumate | 290 ± 180 | 130 ± 100 |
Phenylbutazone | 2200 ± 400 | 600 ± 180 |
Piroxicam | 2600 ± 500 | 690 ± 390 |
Salicylate* | 3300 ± 1400 | 1750 ± 400 |
Sulindac Sulfide* | 40 ± 10 | 190 ± 180 |
Sulindac Sulfoxide* | 580 ± 260 | 660 ± 520 |
Sulindac Sulfone* | 280 ± 10 | 580 ± 140 |
Tiaprofenate | 1400 ± 400 | 440 ± 230 |
Tolmetin | 1400 ± 100 | 1900 ± 170 |
↵1-a IC50 values (mean ± S.D.,n ≥ 3) for inhibition of cross-linking of125I-[Nle15]-gastrin2,17 to TPα were determined as described in “Materials and Methods.”
↵1-b IC50 values (mean ± S.D., n ≥ 3) for inhibition of growth of LIM 1215 colon carcinoma cells by NSAIDs were determined as described in “Materials and Methods.” The values for the NSAIDs marked with an asterisk have been reported previously (Murphy et al., 1998). Similar values have been reported for the human colon carcinoma cell lines HT 29, SW 480 and DLD-1 by Hixson and coworkers (Hixson et al., 1994).